康泰生物(300601.SZ)：签署《许可终止协议》

Core Viewpoint - The company has decided to terminate the licensing agreement with AstraZeneca for the development, production, and commercialization of the ChAdOx1 adenovirus vector COVID-19 vaccine due to significant changes in the COVID-19 vaccine strains and market environment [1] Group 1: Licensing Agreement Details - On August 20, 2020, the company signed a licensing agreement with AstraZeneca, granting exclusive rights to develop, produce, and commercialize the COVID-19 vaccine in mainland China [1] - The termination of the licensing agreement was mutually agreed upon after careful consideration of changes in the COVID-19 vaccine landscape and the company's resource allocation [1] Group 2: Impact on the Company - The termination of the licensing agreement is deemed a prudent decision aligned with the company's development strategy [1] - The company asserts that this decision will not have a significant impact on its production operations, core business activities, or financial status [1] - There are no concerns regarding the protection of the interests of the company and its shareholders, particularly minority shareholders [1]